OR WAIT null SECS
To conduct metabolite identification supporting preclinical development and early human studies, Covance Inc. has announced a substantial increase in global capacity and expertise. The expansion increases Covance’s global scientific staff and equipment supporting metabolite identification to enable clients to start studies sooner and obtain results faster.
Covance’s global scientific staff dedicated to metabolite identification studies now includes 14 senior scientists located in Madison, Wisconsin and Harrogate, United Kingdom. New equipment brings the total instrumentation to five accurate mass Spectrometers, six QTrap mass spectrometers and access to nuclear magnetic resonance (NMR) analysis for unequivocal structural identification.
The additions at the Madison facility will better accommodate increased client demand resulting from the Food and Drug Administration’s (FDA) recent Guidance for Industry on Safety Testing of Drug Metabolites. The Guidance recommends when and how to identify and characterize drug metabolites whose nonclinical toxicity needs evaluation.
Covance has conducted hundreds of metabolite identification studies to date in Madison, Wisconsin and Harrogate, UK. Globally, Covance provides comprehensive drug metabolism services to pharmaceutical companies and hundreds of smaller pharmaceutical and biotech companies.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.